Skip to main content
Springer logoLink to Springer
. 2023 Dec 28;397(7):4799–4808. doi: 10.1007/s00210-023-02910-x

Intravitreal ranibizumab injection is associated with an increased risk of chronic kidney disease: a population-based study in Taiwan

Chang-Hsu Chen 1,2,3,4, Paik Seong Lim 2,4,5, Tsai-Kun Wu 2,5, Wu-Lung Chuang 6,7, Teng-Shun Yu 8,9, Fuu-Jen Tsai 10,11,12,13, Chuan-Mu Chen 1,3,4,14,✉,#, Kuang-Hsi Chang 5,15,16,17,✉,#
PMCID: PMC11166851  PMID: 38153512

Abstract

Systemic vascular endothelial growth factor (VEGF) blockade has been the top adjunctive chemotherapy since 1990. Anti-VEGF therapy has also been associated with worsened renal function in some patients. However, the association between patient outcomes and use of intravitreal VEGF inhibitors remains controversial. Thus, it is necessary to determine the action mechanism and long-term renal effects of ranibizumab. The National Health Insurance Research Database (NHIRD) is one of the largest global databases that are extensively used for epidemiological research. NHIRD contains the medical information of all insureds, such as inpatient, outpatient, emergency, and traditional Chinese medicine records. We selected subjects aged ≥ 20 years who recently administered ranibizumab for the ranibizumab cohort. Non-ranibizumab cohort consisted of subjects who did not receive ranibizumab, and the index date was a random date between 2008 and 2018. We excluded subjects with missing sex and age records and those in which the date of primary outcome was before the index date. The two cohorts were matched via 1:1 propensity score matching based on sex, age, index year, hypertension, diabetes mellitus, hyperlipidemia, stroke, coronary artery disease, alcoholism, chronic obstructive pulmonary disease, and age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Medical confounders were angiotensin I-converting enzyme inhibitors, statins, corticosteroids, VEGF inhibitors including bevacizumab and aflibercept, lithium, amphotericin B, adefovir, NSAIDS, cisplatin, and calcineurin inhibitors. Among 48,248 participants aged ≥ 20 years, 24,136 (50%) received ranibizumab (13,565 male [56.20%] and 10,571 female [43.80%]). Moreover, 24,136 participants who did not receive ranibizumab were matched by age, sex, comorbidities, and medications. Subjects who received ranibizumab exhibited a significantly higher risk of CKD than those who did not receive ranibizumab (adjusted hazard ratio = 1.88, 95% CI = 1.79–1.96). Our findings revealed that exposure to intravitreal ranibizumab is an independent risk factor for CKD. Therefore, physicians and ophthalmologists should make the patients aware of such a correlation to increase patient safety and decrease the CKD burden.

Keywords: Ranibizumab; Vascular endothelial growth factor (VEGF); Chronic kidney disease, National Health Insurance Research Database (NHIRD)

Introduction

Systemic vascular endothelial growth factor (VEGF) blockade has been the top adjunctive chemotherapy since 1990 (Hanna et al. 2019). Anti-angiogenic agents are widely used to treat various malignancies, such as non-small cell lung cancer, renal cell carcinoma, and colorectal cancer (Hanna et al. 2019; Phadke et al. 2021). VEGF inhibitors are powerful tools used to delay neovascularization and prevent retinal damage (Phadke et al. 2021). Intravitreal anti-VEGF therapy is widely used for the treatment of proliferative diabetic retinopathy/diabetic macular edema, age-related macular degeneration, and central retinal vein occlusion (Hanna et al. 2019; Hanna et al. 2022). Bevacizumab was the first anti-VEGF antibody used off-label via intravitreal injections to treat retinal neovascularization (Hanna et al. 2022). Aflibercept and ranibizumab have also been approved by the U.S. Food and Drug Administration for ophthalmological use (Hanna et al. 2019, 2022).

Compared to systemic administration, intravitreal use of anti-VEGF agents was initially considered to be a safer choice (Hanna et al. 2019). However, systemic exposure was reported to be more impactful in later studies (Avery et al. 2014, 2017). Bevacizumab, aflibercept, and ranibizumab are immediately circulated in the body (Avery et al. 2014, 2017). Specifically, ranibizumab is rapidly cleared from the bloodstream and exerts the weakest anti-VEGF effects (Avery et al. 2014, 2017). Aflibercept is the most effective in decreasing the plasma-free VEGF levels (Avery et al. 2014, 2017). Moreover, multiple intravitreal injections prolong the period of detectable systemic exposure of the drug (Avery et al. 2014).

Systemic toxicity of intravitreal VEGF blockade is a serious concern. Several studies have reported that intravitreal anti-VEGF therapy is associated with increased hypertension (Rasier et al. 2009), proteinuria (Chung et al. 2020), and thrombotic events (Schmid et al. 2015; Avery and Gordon 2016). Anti-VEGF therapy has also been associated with worsened renal function in some patients (Diabetic Retinopathy Clinical Research N et al. 2007; Jalalonmuhali et al. 2020). Serial retrospective studies have reported that intravitreal bevacizumab increases the risk of mortality in patients with age-related macular degeneration (Hanhart et al. 2017, 2018a, b). However, the association between patient outcomes and use of intravitreal VEGF inhibitors remains controversial, as some studies have reported no significant effects of these inhibitors on hypertension (Risimic et al. 2013; Glassman et al. 2018), proteinuria (Glassman et al. 2018; O’Neill et al. 2019; Bagheri et al. 2018), renal function (O’Neill et al. 2019; Bagheri et al. 2018; Kameda et al. 2018), and mortality (Dalvin et al. 2019) in patients.

Among currently available intravitreal VEGF inhibitors, ranibizumab is less potent and considered a safer option to treat patients with comorbidities (Hanna et al. 2022). Moreover, ranibizumab exhibited the least systemic exposure and decrease in plasma VEGF levels after intravitreal injection compared to bevacizumab and aflibercept (Avery et al. 2014, 2017). Ranibizumab also reduced nephrotoxicity, without any significant effect on glomeruli, in an animal study (Tschulakow et al. 2014). In contrast, several studies have reported that ranibizumab decreases renal function, worsens proteinuria, and causes thrombotic microangiopathy (Phadke et al. 2021; Pelle et al. 2011; Morales et al. 2017). As it is prioritized in the treatment of patients with comorbidities, it is necessary to determine the action mechanism and long-term renal effects of ranibizumab (Hanna et al. 2019; Estrada et al. 2019).

In this nationwide cohort study, we used propensity score matching to determine the risk of chronic kidney disease (CKD) in patients receiving intravitreal ranibizumab injections in Taiwan.

Methods

Data source

Since March, 1995, > 99% of the Taiwanese population has been insured via the National Health Insurance (NHI) program of Taiwan. National Health Insurance Research Database (NHIRD) is one of the largest global databases that are extensively used for epidemiological research. NHIRD contains the medical information of all insureds, such as inpatient, outpatient, emergency, and traditional Chinese medicine records. Patient diagnoses were recorded according to the International Classification of Diseases, 9th Revision, Clinical Modification, and International Classification of Diseases, 10th Revision (ICD-9-CM and ICD-10-CM). All analyses were conducted at the China Medical University branch center of the Ministry of Health and Welfare. This study was approved by the Institutional Review Board of China Medical University (CMUH110-REC3-133).

Subject inclusion and exclusion criteria

We selected subjects aged ≥ 20 years recently administered ranibizumab for the ranibizumab cohort, and the index date was defined as the first date of ranibizumab treatment between 2008 and 2018. Non-ranibizumab cohort consisted of subjects who did not receive ranibizumab, and the index date was a random date between 2008 and 2018. We excluded subjects with missing sex and age records and those in which the date of primary outcome was before the index date. The two cohorts were matched via 1:1 propensity score matching based on sex, age, index year, comorbidities, and medications. In the following section, definitions for comorbidities and medications will be expounded upon.

Primary outcomes, comorbidities, and medications

The primary endpoint was CKD in this study. We followed up the patients until CKD was diagnosed at the end of 2019 or until they withdrew from the NHI. CKD was defined as ICD-9-CM code 585 and ICD-10-CM code N18. Comorbidities with potential confounding factors were extracted from the database from January 1, 2008 to the index date of the subject. CKD-related comorbidities consisted of hypertension (ICD-9-CM code 401–405 and ICD-10-CM codes I10, I11, I12, I13, I15, and N26.2), diabetes mellitus (ICD-9-CM code 250 and ICD-10-CM code E08-E13), hyperlipidemia (ICD-9-CM code 272 and ICD-10-CM codes E71.30, E75.21, E75.22, E75.24, E75.3, E75.5, E75.6, E77, E78.0, E78.1, E78.2, E78.3, E78.4, E78.5, E78.6, E78.70, E78.79, E78.8, and E78.9), stroke (ICD-9-CM code 430–438 and ICD-10-CM code I60-I69), coronary artery disease (CAD; ICD-9-CM code 410–414 and ICD-10-CM code I20-I25), alcoholism (ICD-9-CM codes 291, 303, 305.0, 571.0–571.3, 790.3, V11.3, and V79.1 and ICD-10-CM codes F10, K70, R78.0, and Z65.8), chronic obstructive pulmonary disease (COPD; ICD-9-CM codes 490–496 and 504–506 and ICD-10-CM codes J40-J47 and J64-J68), and age-related macular degeneration (AMD; ICD-9-CM codes 362.52, ICD-10-CM: H35.32), retinal vein occlusion (RVO; ICD-9-CM: 362.36, ICD-10-CM: H34.83), and diabetic macular edema (DME; ICD-9-CM: 362.01, ICD-10-CM: E11.311). Medical confounders were angiotensin I-converting enzyme inhibitors, statins, corticosteroids, VEGF inhibitors including bevacizumab and aflibercept, lithium, amphotericin B (AmB), adefovir, NSAIDS, cisplatin, and calcineurin inhibitors (CNIs). Medication usage was defined as receiving a prescription after the index date.

Statistical analyses

Standardized mean difference (SMD) was used to estimate the differences in baseline characteristics between the case and control groups. Density of CKD events per 1000 person-years was calculated for both cohorts during the study period. Cox model was used to compare the risk of CKD between the case and control groups. Model 1 included a crude estimate of the hazard ratio and a 95% confidence interval (CI). Model 2 was adjusted for age, sex, comorbidities, and medications, and it estimated the adjusted HR (AHR). Moreover, Kaplan–Meier analysis and log-rank tests were used to estimate the difference in the cumulative incidence of CKD between the two groups.

Results

Among 48,272 participants aged ≥ 20 years, 24,136 (50%) received ranibizumab (13,565 men [56.20%] and 10,571 women [43.80%]). Moreover, 24,136 participants who did not receive ranibizumab were matched by age, sex, comorbidities, and medications (Table 1), and the baseline characteristics were found to be well-balanced. Mean (standard deviation) ages of subjects in the case and control groups were 66.23 (12.13) and 66.42 years (12.79), respectively. In the non-ranibizumab and ranibizumab cohorts, the top three comorbidities were hypertension (69.84 vs. 72.65%), diabetes mellitus (61.09 vs. 61.71%), and hyperlipidemia (59.40 vs. 64.36%). Compared with those in the control group, subjects in the case group had similar proportions of comorbidities and medications.

Table 1.

Characteristics of individuals with and without ranibizumab treatment

Covariates Control (n = 24,136) Ranibizumab (n = 24,136) SMD
n % n %
Age
  20 − 49 2051 8.50 1858 7.70 0.029
  50 − 64 8666 35.90 8916 36.94 0.022
  ≥ 65 13,419 55.60 13,362 55.36 0.005
  Mean ± SD 66.42 12.79 66.23 12.13 0.015
Gender 0.003
  Women 10,535 43.65 10,571 43.80
  Men 13,601 56.35 13,565 56.20
Comorbidity
  HT 17,536 72.65 16,857 69.84 0.062
  DM 15,618 64.71 14,744 61.09 0.075
  HL 15,535 64.36 14,336 59.40 0.102
  Stroke 4853 20.11 4344 18.00 0.054
  CAD 7287 30.19 6427 26.63 0.079
  COPD 7197 29.82 6789 28.13 0.037
  AMD 4451 18.44 5228 21.66 0.080
  RVO 1176 4.87 1115 4.62 0.012
  DME 6826 28.28 6026 24.97 0.075
Medication
  ACEI 3831 15.87 3455 14.31 0.044
  Statin 14,282 59.17 13,953 57.81 0.028
  Corticosteroid 14,734 61.05 14,154 58.64 0.049
  VEGF 837 3.47 749 3.10 0.020
  Lithium 129 0.53 27 0.11 0.075
  AmB 36 0.15 22 0.09 0.017
  Adefovir 18 0.07 6 0.02 0.022
  NSAIDS 15,486 64.16 15,162 62.82 0.028
  Cisplatin 320 1.33 168 0.70 0.063
  CNIs 405 1.68 283 1.17 0.043

SMD standardized mean difference, HT hypertension, DM diabetes mellitus, HL hyperlipidemia, CAD coronary heart disease, COPD chronic obstructive pulmonary disease, AMD age-related macular degeneration, RVO retinal vein occlusion, DME diabetic macular edema, ACEI angiotensin-converting enzyme inhibitors, VEGF inhibitors including bevacizumab and aflibercept, AmB amphotericin B, NSAIDS non-steroidal anti-inflammatory drugs, CNIs calcineurin inhibitors

Table 2 presents the association between CKD incidence and patients with and without ranibizumab treatment. Subjects who received ranibizumab exhibited a significantly higher risk of CKD than those who did not receive ranibizumab (AHR = 1.88, 95% CI = 1.79–1.96). Compared with the female subjects, male subjects had higher risk of CKD (AHR = 1.29, 95% CI = 1.23–1.35). Compared with subjects in the 20–49 age group, subjects in the 50–64 age group and those > 65 years had a lower risk of CKD. The adjusted HRs were 0.76 (0.70–0.83) and 0.82 (0.75–0.89), respectively. In addition, patients with hypertension (adjusted HR = 1.86, 95% CI = 1.73–1.99), diabetes mellitus (adjusted HR = 2.37, 95% CI = 2.21–2.54), hyperlipidemia (adjusted HR = 1.19, 95% CI = 1.13–1.26), stroke (adjusted HR = 1.16, 95% CI = 1.10–1.23), CAD (adjusted HR = 1.24, 95% CI = 1.18–1.30), and COPD (adjusted HR = 1.10, 95% CI = 1.04–1.15) exhibited significantly higher risks of CKD than the corresponding groups (AHR > 1; p < 0.05). Moreover, patients who received statin, VEGF inhibitor, lithium, and NSAIDS had significantly lower risks of CKD than the corresponding groups (aHR < 1; p < 0.05).

Table 2.

Risk factor analyses of all subjects for chronic kidney disease (CKD)

Covariates Event PY IR cHR 95% CI aHR 95% CI
Ranibizumab No 2921 89,775 32.54 1.00 1.00
Yes 4865 89,860 54.14 1.67 1.59, 1.75 1.88 1.79, 1.96
Age 20 − 49 647 13,071 49.50 1.00 1.00
50 − 64 2840 66,436 42.75 0.87 0.80, 0.95 0.76 0.70, 0.83
 ≥ 65 4299 100,127 42.94 0.88 0.81, 0.96 0.82 0.75, 0.89
Gender Women 2967 78,381 37.85 1.00 1.00
Men 4819 101,254 47.59 1.26 1.21, 1.32 1.29 1.23, 1.35
Comorbidity
  HT No 1162 55,400 20.97 1.00 1.00
Yes 6624 124,234 53.32 2.52 2.37, 2.68 1.86 1.73, 1.99
  DM No 1320 72,052 18.32 1.00 1.00
Yes 6466 107,583 60.10 3.25 3.06, 3.45 2.37 2.21, 2.54
  HL No 2256 72,107 31.29 1.00 1.00
Yes 5530 107,528 51.43 1.63 1.55, 1.71 1.19 1.13, 1.26
  Stroke No 5991 147,641 40.58 1.00 1.00
Yes 1795 31,994 56.11 1.38 1.30, 1.45 1.16 1.1, 1.23
  CAD No 5226 130,102 40.17 1.00 1.00
Yes 2560 49,533 51.68 1.29 1.23, 1.35 1.24 1.18, 1.30
  Alcoholism No 7636 176,816 43.19 1.00 1.00
Yes 150 2819 53.22 1.22 1.04, 1.43 1.23 1.04, 1.44
  COPD No 5512 129,320 42.62 1.00 1.00
Yes 2274 50,315 45.20 1.06 1.01, 1.11 1.1 1.04, 1.15
  AMD No 6679 140,333 47.59 1.00 1.00
Yes 1107 39,301 28.17 0.6 0.56, 0.64 0.9 0.84, 0.97
  RVO No 7537 173,260 43.50 1.00 1.00
Yes 249 6374 39.06 0.88 0.78, 1.00 0.83 0.73, 0.94
  DME No 4553 133,506 34.10 1.00 1.00
Yes 3233 46,128 70.09 2.04 1.95, 2.13 1.36 1.30, 1.43
Medication
  ACEI No 6372 149,160 42.72 1.00 1.00
Yes 1414 30,474 46.40 1.10 1.04, 1.16 0.99 0.94, 1.05
  Statin No 2578 69,858 36.90 1.00 1.00
Yes 5208 109,777 47.44 1.29 1.23, 1.35 0.75 0.71, 0.80
  Corticosteroid No 2099 68,971 30.43 1.00 1.00
Yes 5687 110,664 51.39 1.69 1.61, 1.78 1.1 1.04, 1.16
  VEGF No 7649 172,996 44.21 1.00 1.00
Yes 137 6639 20.64 0.47 0.40, 0.56 0.55 0.46, 0.65
  Lithium No 7779 178,945 43.47 1.00 1.00
Yes 7 690 10.15 0.24 0.11, 0.50 0.31 0.15, 0.66
  AmB No 7776 179,401 43.34 1.00 1.00
Yes 10 234 42.81 0.99 0.53, 1.84 1.4 0.75, 2.61
  Adefovir No 7781 179,527 43.34 1.00 1.00
Yes 5 107 46.59 1.10 0.46, 2.64 1.59 0.66, 3.81
  NSAIDS No 3935 51,495 76.42 1.00 1.00
Yes 3851 128,140 30.05 0.40 0.38, 0.41 0.41 0.39, 0.43
  Cisplatin No 7743 178,014 43.50 1.00 1.00
Yes 43 1621 26.53 0.61 0.45, 0.82 0.83 0.61, 1.12
  CNIs No 7677 176,770 43.43 1.00 1.00
Yes 109 2865 38.05 0.89 0.73, 1.07 1.13 0.93, 1.37

Event number of patients with of CKD, PY person-year, IR incidence rate (per 1000 person-years), cHR crude hazard ratio, aHR adjusted hazard ratio adjusted for age, gender, comorbidities, and medications, CI confidence interval, HT hypertension, DM diabetes mellitus, HL hyperlipidemia, CAD coronary heart disease, COPD chronic obstructive pulmonary disease, AMD age-related macular degeneration, RVO retinal vein occlusion, DME diabetic macular edema, ACEI angiotensin converting enzyme inhibitors, VEGF inhibitors including bevacizumab and aflibercept, AmB amphotericin B, NSAIDS non-steroidal anti-inflammatory drugs, CNIs calcineurin inhibitors

Table 3 presents the subgroup analysis results: subjects with varying sex, age, comorbidities, and medications; ranibizumab users tended to have a lower risk of CKD than non-ranibizumab users (adjusted HR > 1, p-value < 0.05).

Table 3.

Incidence and hazard ratio of CKD in individuals with and without ranibizumab treatment based on age, gender, comorbidities, and medications

Covariates Control Ranibizumab cHR (95% CI) aHR (95% CI)
Event PY IR Event PY Rate
Age 20 − 49 157 7808 20.11 490 5263 93.10 4.50 3.76, 5.40 4.50 3.76, 5.40
50 − 64 906 33,992 26.65 1934 32,443 59.61 2.22 2.06, 2.41 2.22 2.06, 2.41
 ≥ 65 1858 47,974 38.73 2441 52,154 46.80 1.21 1.14, 1.29 1.21 1.14, 1.29
Gender Women 1129 39,410 28.65 1838 38,971 47.16 1.65 1.53, 1.77 1.64 1.52, 1.77
Men 1792 50,365 35.58 3027 50,889 59.48 1.68 1.59, 1.78 1.69 1.60, 1.80
Comorbidity
  HT No 386 26,183 14.74 776 29,217 26.56 1.80 1.59, 2.03 1.81 1.60, 2.05
Yes 2535 63,592 39.86 4089 60,643 67.43 1.7 1.61, 1.78 1.72 1.63, 1.81
  DM No 581 32,800 17.71 739 39,252 18.83 1.05 0.94, 1.17 0.99 0.89, 1.10
Yes 2340 56,975 41.07 4126 50,608 81.53 1.98 1.88, 2.08 1.98 1.89, 2.09
  HL No 839 32,806 25.57 1417 39,301 36.06 1.41 1.30, 1.54 1.40 1.29, 1.53
Yes 2082 56,968 36.55 3448 50,559 68.20 1.87 1.77, 1.97 1.87 1.78, 1.98
  Stroke No 2178 73,099 29.80 3813 74,542 51.15 1.72 1.63, 1.81 1.73 1.64, 1.82
Yes 743 16,676 44.56 1052 15,318 68.68 1.54 1.41, 1.70 1.56 1.42, 1.71
  CAD No 1840 63,824 28.83 3386 66,277 51.09 1.78 1.68, 1.88 1.79 1.69, 1.89
Yes 1081 25,950 41.66 1479 23,583 62.72 1.51 1.39, 1.63 1.50 1.39, 1.63
  Alcoholism No 2846 87,964 32.35 4790 88,852 53.91 1.67 1.59, 1.75 1.67 1.60, 1.75
Yes 75 1811 41.42 75 1008 74.42 1.82 1.32, 2.51 1.90 1.37, 2.62
  COPD No 1980 64,595 30.65 3532 64,725 54.57 1.78 1.69, 1.88 1.79 1.70, 1.89
Yes 941 25,180 37.37 1333 25,135 53.03 1.42 1.31, 1.55 1.41 1.30, 1.53
  AMD No 2442 73,854 33.07 4237 66,479 63.73 1.92 1.83, 2.02 1.92 1.83, 2.02
Yes 479 15,921 30.09 628 23,381 26.86 0.88 0.78, 1.00 0.90 0.80, 1.02
  RVO No 2775 86,137 32.22 4762 87,123 54.66 1.70 1.62, 1.78 1.71 1.63, 1.79
Yes 146 3637 40.14 103 2737 37.63 0.94 0.73, 1.21 0.94 0.73, 1.21
  DME No 1592 64,629 24.63 2961 68,878 42.99 1.75 1.65, 1.86 1.74 1.64, 1.85
Yes 1329 25,146 52.85 1904 20,982 90.74 1.70 1.59, 1.83 1.70 1.59, 1.83
Medication
  ACEI No 2353 74,002 31.80 4019 75,158 53.47 1.69 1.60, 1.78 1.69 1.60, 1.77
Yes 568 15,772 36.01 846 14,702 57.54 1.60 1.44, 1.78 1.63 1.47, 1.82
  Statin No 991 33,432 29.64 1587 36,425 43.57 1.49 1.37, 1.61 1.47 1.36, 1.59
Yes 1930 56,342 34.25 3278 53,435 61.35 1.79 1.70, 1.90 1.81 1.71, 1.91
  Corticosteroid No 792 32,613 24.28 1307 36,358 35.95 1.50 1.37, 1.64 1.48 1.35, 1.62
Yes 2129 57,161 37.25 3558 53,502 66.50 1.79 1.70, 1.89 1.81 1.72, 1.91
  VEGF No 2857 86,566 33.00 4792 86,430 55.44 1.68 1.61, 1.76 1.69 1.61, 1.77
Yes 64 3209 19.95 73 3430 21.28 1.03 0.74, 1.45 1.04 0.74, 1.46
  NSAIDS No 1379 25,862 53.32 2556 25,633 99.72 1.87 1.75, 1.99 1.87 1.75, 1.99
Yes 1542 63,912 24.13 2309 64,227 35.95 1.48 1.39, 1.58 1.47 1.38, 1.57
  Cisplatin No 2899 88,766 32.66 4844 89,248 54.28 1.67 1.59, 1.74 1.67 1.59, 1.75
Yes 22 1009 21.80 21 612 34.31 1.44 0.79, 2.63 1.34 0.72, 2.50
  CNIs No 2866 88,023 32.56 4811 88,747 54.21 1.67 1.60, 1.75 1.67 1.60, 1.75
Yes 55 1752 31.40 54 1113 48.51 1.59 1.09, 2.31 1.52 1.03, 2.22

Event number of patients with of CKD, PY person-year, IR incidence rate (per 1000 person-years), cHR crude hazard ratio, aHR adjusted hazard ratio, adjusted for age, gender, comorbidities, and medications, CI confidence interval, HT Hypertension, DM diabetes mellitus, HL hyperlipidemia, CAD coronary heart disease, COPD chronic obstructive pulmonary disease, AMD age-related macular degeneration, RVO retinal vein occlusion, DME diabetic macular edema, ACEI angiotensin converting enzyme inhibitors, VEGF inhibitors including bevacizumab and aflibercept, AmB amphotericin B, NSAIDS non-steroidal anti-inflammatory drugs, CNIs calcineurin inhibitors

As shown in Fig. 1, the cumulative incidence of CKD in the ranibizumab cohort was significantly higher than that in the non-ranibizumab cohort (log-rank test p < 0.001).

Fig. 1.

Fig. 1

Comparison of cumulative incidence of CKD between patients receiving ranibizumab and those not receiving the treatment

Discussion

Our findings provide evidence that intravitreal ranibizumab, a VEGF inhibitor, is associated with a higher risk of CKD. Using propensity score matching, we created a control group with a comparable distribution to the ranibizumab group regarding gender, age, comorbidities, and medication. Multivariate analysis revealed increased risk of CKD in the ranibizumab group. Subgroup analysis also revealed that ranibizumab was associated with a higher risk of CKD.

To the best of our knowledge, this is the first population-based study to highlight the correlation between intravitreal anti-VEGF therapy and long-term renal patient outcomes. Although several case studies suggested the nephrotoxicity of intravitreal VEGF inhibitors, only a few focused on their chronic effects on renal function (Hanna et al. 2019, 2022). In a retrospective cohort of 85 diabetic macular edema cases, O’Neill et al. reported no association between glomerular filtration rate decline and intravitreal injections of VEGF inhibitors, mainly ranibizumab, in a mean duration of 31 months (O’Neill et al. 2019). Another randomized study of 660 participants with diabetic macular edema revealed that urine albumin–creatinine ratio does not change significantly after intravitreal aflibercept, bevacizumab, and ranibizumab treatment for 52 weeks (Glassman et al. 2018). The first study cohort may be too small to detect rare renal toxicities (O’Neill et al. 2019). In the second study cohort, chronic renal outcomes may not be affected due to the short following period (Glassman et al. 2018). Most studies only focused on diabetic patients with macular edema. Therefore, our study provides robust evidence for the association between intravitreal use of ranibizumab and increased risk of CKD over a long period using a nationwide database. Meanwhile, ranibizumab was selected as the representative treatment in our study because intravitreal bevacizumab is non-reimbursable, and its data is lacking in NHID. Ranibizumab was the first intravitreal anti-VEGF therapy reimbursed by NHI, and it was more clinically experienced than aflibercept before 2018. Although some aflibercept users might be included in the control group, the risk of ranibizumab was still significant. Since our study showed that even less potent and safer ranibizumab was associated with an increased risk of CKD, it is worthwhile to include aflibercept to compare their effects on kidney function and investigate whether drug class effects of adverse long-term renal outcomes exist by using an updated database in the future study.

In Taiwan, old age is associated with a high risk of CKD (Kuo et al. 2007), and CKD is more prevalent in group aged > 65 years (Wen et al. 2008). Age distribution of our cohort revealed that the patients treated with ranibizumab who were eligible for reimbursement, such as those with diabetic macular edema, age-related macular degeneration, polypoidal choroidal vasculopathy, and central or branch retinal vein occlusion with macular edema, were mainly elderly patients. As the elderly are more susceptible to renal injury, several measures have been proposed to minimize the nephrotoxicity of VEGF inhibitors (Estrada et al. 2019). Interestingly, our study revealed a higher risk of developing CKD in the group aged < 50 years after adjusting several covariates including diabetes. Here, we inferred that the young ranibizumab users mostly consisted of patients with diabetic macular edema based on previous epidemiological reports (Ho et al. 2008; Chang et al. 2018; Chang and Wu 2009). Since the development of diabetic retinopathy is correlated with the duration of diabetes (Zhang et al. 2010; Lee et al. 2015), the age of diabetic onset in young diabetic patients using ranibizumab may be considered earlier than old diabetic users. Several studies have shown that the young age of diabetes onset might be an important risk factor for renal complications (Magliano et al. 2020; Wu et al. 2021; Lee et al. 2023). One recent large prospective cohort study in China revealed that the young age of onset of diabetes synergistically enhanced the risk of CKD among the influence of diabetes duration (Wu et al. 2021). Another large population study in Korea also showed that patients with young-onset diabetes (age < 40 years) had 70% higher risk of developing CKD than the late-onset group (Lee et al. 2023). Our finding was consistent with the previous literatures. Current evidence proposed that more rapid β cell failure and obesity in young-onset patients than in late-onset patients leads to worse disease progression (Magliano et al. 2020). Besides, the correlation between intravitreal VEGF antagonist-related renal damage and diabetic nephropathy has also been reported (Morales et al. 2017; Hanna et al. 2020; Shye et al. 2020). Because our cohort was lacking in several parameters such as oral glucose tolerance test, albuminuria, or body mass index, we were unable to determine the possible mechanisms of higher risk of CKD in young ranibizumab users. Nonetheless, our result highlighted the need for clinical awareness, aggressive treatment, and closer collaboration between nephrologists and ophthalmologists to reduce renal progression in ranibizumab users aged < 50 years.

Mechanisms underlying the associations reported here remain unknown. Anti-VEGF nephrotoxicity is associated with various renal pathological manifestations, such as focal segmental glomerulosclerosis, minimal changes disease, membranous nephropathy, acute interstitial nephritis, and thrombotic microangiopathy (Hanna et al. 2019, 2022; Estrada et al. 2019). Downstream effects of VEGF inhibition on podocytes and glomerular endothelial cells have been proposed (Hanna et al. 2022; Estrada et al. 2019). For example, sequestration of VEGF leads to complement activation and increased nuclear factor-κB signaling in both podocytes and endothelial cells, subsequently causing thrombotic microangiopathy (Estrada et al. 2019). Because patients receiving intravitreal ranibizumab are not required specific monitoring, delayed recognition of subclinical renal injury may potentially occur. Acute kidney injury and CKD are intercorrelated (Okusa et al. 2009; Coca et al. 2012). Notably, patients recovering from acute kidney injury may be at risk of CKD due to nephron loss, incomplete repair, inflammation, fibrosis, and epigenetic changes (Wang and Zhang 2022; Tanemoto et al. 2022). As our study lacked serial clinical and laboratory parameters, such as blood pressure or urine protein levels, further prospective studies are needed to examine the causality and time course of the association between intravitreal VEGF inhibitors and risk of CKD.

This study has several limitations. Although we used the propensity score matching method and adjusted for extensively available covariates, we could not account for other residual confounding factors that contributed to the development of CKD. For example, data on cigarette smoking and obesity, two important risk factors for age-related macular degeneration and CKD (Wen et al. 2008; Chakravarthy et al. 2010), were lacking in our cohort. In addition, control group was selected according to the propensity score, and hence, did not reflect the actual health situation of the general population. This may have resulted in an underestimation of CKD risk. Furthermore, our findings may have surveillance bias as patients receiving ranibizumab were more likely to undergo laboratory examinations that detected CKD due to more frequent contact with the medical care system than those who did not receive ranibizumab. However, Taiwan NHI program enrolled > 99.99% of residents, removed some barriers, and provided free health care in the low urbanization areas (Cheng and Chiang 1997; Huang et al. 2006). Therefore, surveillance bias may be limited.

Using ICD codes to define comorbidities and incident CKD may have decreased the sensitivity of diagnosis and resulted in inaccurate administrative data. Therefore, a sampling bias may have occurred. In addition, we could not analyze whether dose accumulation is associated with CKD as reducing the dose and frequency of intravitreal VEGF inhibitors is necessary for treating high-risk patients (Hanna et al. 2019). Finally, we could not determine whether any distinct disease in ranibizumab users increased the risk of CKD.

The main strength of this study is the use of a large community-based cohort with a 10-year follow-up period. We examined the relationship between drug exposure and long-term patient outcomes in a real-world setting. The robustness of our findings was supported by consistent results after adjusting for various medications and comorbidities. Our study is the first to provide evidence for the adverse effects of intravitreal VEGF inhibitors, including low-potency ranibizumab, and their association with the incidence of CKD (Phadke et al. 2021). As it has the highest incidence and prevalence of end-stage renal disease worldwide (Wen et al. 2008), this association should be further validated to aid the public health in Taiwan.

In summary, our findings revealed that exposure to intravitreal ranibizumab is an independent risk factor for CKD. Therefore, physicians and ophthalmologists should make the patients aware of such a correlation to increase patient safety and decrease the CKD burden. However, the specific causal relationships and underlying mechanisms require further investigation.

Author contributions

Conceptualization, K.-H.C. and W.-L.C.; methodology, K.-H.C. and T.-S.Y.; software, T.-S.Y.; validation, C.-H.C., P.S.L., T.-K.W., W.-L.C., T.-S.Y., F.-J.T., C.-M.C., and K.-H.C.; formal analysis, K.-H.C. and T.-S.Y.; investigation, K.-H.C. and T.-S.Y.; resources, C.-H.C. F.-J.T., and K.-H.C.; data curation, K.-H.C. and T.-S.Y.; writing—original draft preparation, C.-H.C., T.-S.Y., and K.-H.C.,; writing—review and editing, K.-H.C.; visualization, C.-H.C. and K.-H.C.; supervision, K.-H.C.; project administration, K.-H.C., and C.-H.C.; funding acquisition, K.-H.C., F.-J.T., and C.-H.C. All authors have read and agreed to the published version of the manuscript. The authors declare that all data were generated in-house and that no paper mill was used.

Funding

This study is supported in part by Tungs’ Taichung Metro Harbor hospital research grant (TTMHH-R1130010), the Ministry of Science and Technology (MOST 111–2321-B-039–005), and China Medical University Hospital (DMR-111–105). Health Data Science Center, China Medical University Hospital provided administrative, technical, and funding support.

Data availability

Data are available from the NHIRD published by Taiwan National Health Insurance Bureau. Due to the ‘Personal Information Protection Act’, data cannot be made publicly available (http://nhird.nhri.org.tw/en/index.html).

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Review Board of China Medical University and Hospital, Taiwan (CMUH109-REC2-031 (CR2)). The IRB waived the consent requirement.

Competing interests

The authors declare no competing interests.

Disclaimer

The funders had no role in the study design, data collection and analysis, the decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Footnotes

Chang-Hsu Chen is first author.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Chuan-Mu Chen and Kuang-Hsi Chang contributed equally to this work.

Contributor Information

Chuan-Mu Chen, Email: chchen1@dragon.nchu.edu.tw.

Kuang-Hsi Chang, Email: kuanghsichang@gmail.com.

References

  1. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134:21–29. doi: 10.1001/jamaophthalmol.2015.4070. [DOI] [PubMed] [Google Scholar]
  2. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636–1641. doi: 10.1136/bjophthalmol-2014-305252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847–1858. doi: 10.1097/IAE.0000000000001493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bagheri S, Dormanesh B, Afarid M, Sagheb MM. Proteinuria and renal dysfunction after intravitreal injection of bevacizumab in patients with diabetic nephropathy: a prospective observational study. Galen Med J. 2018;7:e1299. doi: 10.31661/gmj.v7i0.1299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31. doi: 10.1186/1471-2415-10-31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chang YC, Wu WC. Polypoidal choroidal vasculopathy in Taiwanese patients. Ophthalmic Surg Lasers Imaging. 2009;40:576–581. doi: 10.3928/15428877-20091030-07. [DOI] [PubMed] [Google Scholar]
  7. Chang YS, Lee WJ, Lim CC, et al. Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan. Sci Rep. 2018;8:7486. doi: 10.1038/s41598-018-25864-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cheng SH, Chiang TL. The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment. JAMA. 1997;278:89–93. doi: 10.1001/jama.278.2.89. [DOI] [PubMed] [Google Scholar]
  9. Chung YR, Kim YH, Byeon HE, Jo DH, Kim JH, Lee K. Effect of a single intravitreal bevacizumab injection on proteinuria in patients with diabetes. Transl Vis Sci Technol. 2020;9:4. doi: 10.1167/tvst.9.4.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81:442–448. doi: 10.1038/ki.2011.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dalvin LA, Starr MR, AbouChehade JE, et al. Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol. 2019;137:483–490. doi: 10.1001/jamaophthalmol.2018.6891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Diabetic Retinopathy Clinical Research N. Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860–7. doi: 10.1016/j.ophtha.2007.05.062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30:187–200. doi: 10.1681/ASN.2018080853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Glassman AR, Liu D, Jampol LM, Sun JK. Diabetic retinopathy clinical research n. changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59:1199–205. doi: 10.1167/iovs.17-22853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hanhart J, Comaneshter DS, Freier Dror Y, Vinker S. Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration. BMC Ophthalmol. 2017;17:189. doi: 10.1186/s12886-017-0586-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hanhart J, Comaneshter DS, Freier-Dror Y, Vinker S. Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. Graefes Arch Clin Exp Ophthalmol. 2018;256:651–663. doi: 10.1007/s00417-018-3917-9. [DOI] [PubMed] [Google Scholar]
  17. Hanhart J, Comaneshter DS, Vinker S. Mortality after a cerebrovascular event in age-related macular degeneration patients treated with bevacizumab ocular injections. Acta Ophthalmol. 2018;96:e732–e739. doi: 10.1111/aos.13731. [DOI] [PubMed] [Google Scholar]
  18. Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96:572–580. doi: 10.1016/j.kint.2019.02.042. [DOI] [PubMed] [Google Scholar]
  19. Hanna RM, Tran NT, Patel SS, et al. Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF Blockade-Related TMA After Intravitreal Use. Front Med (Lausanne) 2020;7:579603. doi: 10.3389/fmed.2020.579603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hanna RM, Ahdoot RS, Kim MS, Jhaveri KD, Kalantar-Zadeh K, Kurtz IB. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. Curr Opin Nephrol Hypertens. 2022;31:47–56. doi: 10.1097/MNH.0000000000000760. [DOI] [PubMed] [Google Scholar]
  21. Ho JD, Tsai CY, Liou SW, Tsai RJ, Lin HC. Seasonal variations in the occurrence of retinal vein occlusion: a five-year nationwide population-based study from Taiwan. Am J Ophthalmol. 2008;145:722–728. doi: 10.1016/j.ajo.2007.12.017. [DOI] [PubMed] [Google Scholar]
  22. Huang N, Yip W, Chang HJ, Chou YJ. Trends in rural and urban differentials in incidence rates for ruptured appendicitis under the National Health Insurance in Taiwan. Public Health. 2006;120:1055–1063. doi: 10.1016/j.puhe.2006.06.011. [DOI] [PubMed] [Google Scholar]
  23. Jalalonmuhali M, Tengku Kamalden TAF, Ismail NAS, Yong SY, Teo WT, Lim SK. Adverse renal outcome following administration of intravitreal anti-vascular endothelial growth factor inhibitors in a single tertiary centre in Malaysia. Nephrol Dialysis Transplant. 2020;35:gfaa142.P0590. doi: 10.1093/ndt/gfaa142.P0590. [DOI] [Google Scholar]
  24. Kameda Y, Babazono T, Uchigata Y, Kitano S. Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease. J Diabetes Investig. 2018;9:937–939. doi: 10.1111/jdi.12771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis. 2007;49:46–55. doi: 10.1053/j.ajkd.2006.10.007. [DOI] [PubMed] [Google Scholar]
  26. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye vis (lond) 2015;2:17. doi: 10.1186/s40662-015-0026-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lee J, Lee S-H, Yoon K-H, Cho JH, Han K, Yang Y. Risk of developing chronic kidney disease in young-onset type 2 diabetes in Korea. Sci Rep. 2023;13:10100. doi: 10.1038/s41598-023-36711-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Magliano DJ, Sacre JW, Harding JL, Gregg EW, Zimmet PZ, Shaw JE. Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. Nat Rev Endocrinol. 2020;16:321–331. doi: 10.1038/s41574-020-0334-z. [DOI] [PubMed] [Google Scholar]
  29. Morales E, Moliz C, Gutierrez E. Renal damage associated to intravitreal administration of ranibizumab. Nefrologia. 2017;37:653–655. doi: 10.1016/j.nefro.2016.10.011. [DOI] [PubMed] [Google Scholar]
  30. O’Neill RA, Gallagher P, Douglas T, et al. Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease. BMC Nephrol. 2019;20:478. doi: 10.1186/s12882-019-1650-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Okusa MD, Chertow GM, Portilla D. Acute Kidney Injury Advisory Group of the American Society of N. The nexus of acute kidney injury, chronic kidney disease, and World Kidney Day 2009. Clin J Am Soc Nephrol. 2009;4:520–2. doi: 10.2215/CJN.06711208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pelle G, Shweke N, Duong Van Huyen JP, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57:756–9. doi: 10.1053/j.ajkd.2010.11.030. [DOI] [PubMed] [Google Scholar]
  33. Phadke G, Hanna RM, Ferrey A, et al. Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration. Clin Kidney J. 2021;14:2158–2165. doi: 10.1093/ckj/sfab066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond) 2009;23:1714–1718. doi: 10.1038/eye.2008.360. [DOI] [PubMed] [Google Scholar]
  35. Risimic D, Milenkovic S, Nikolic D, et al. Influence of intravitreal injection of bevacizumab on systemic blood pressure changes in patients with exudative form of age-related macular degeneration. Hellenic J Cardiol. 2013;54:435–440. [PubMed] [Google Scholar]
  36. Schmid MK, Bachmann LM, Fas L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2015;99:141–146. doi: 10.1136/bjophthalmol-2014-305149. [DOI] [PubMed] [Google Scholar]
  37. Shye M, Hanna RM, Patel SS, et al. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. Clin Kidney J. 2020;13:969–980. doi: 10.1093/ckj/sfaa049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Tanemoto F, Nangaku M, Mimura I. Epigenetic memory contributing to the pathogenesis of AKI-to-CKD transition. Front Mol Biosci. 2022;9:1003227. doi: 10.3389/fmolb.2022.1003227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tschulakow A, Christner S, Julien S, Ludinsky M, van der Giet M, Schraermeyer U. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS ONE. 2014;9:e113701. doi: 10.1371/journal.pone.0113701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wang Z, Zhang C. From AKI to CKD: maladaptive repair and the underlying mechanisms. Int J Mol Sci. 2022;23:10880. doi: 10.3390/ijms231810880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371:2173–2182. doi: 10.1016/S0140-6736(08)60952-6. [DOI] [PubMed] [Google Scholar]
  42. Wu H, Lau ESH, Yang A, et al. Young age at diabetes diagnosis amplifies the effect of diabetes duration on risk of chronic kidney disease: a prospective cohort study. Diabetologia. 2021;64:1990–2000. doi: 10.1007/s00125-021-05494-4. [DOI] [PubMed] [Google Scholar]
  43. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304:649–656. doi: 10.1001/jama.2010.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data are available from the NHIRD published by Taiwan National Health Insurance Bureau. Due to the ‘Personal Information Protection Act’, data cannot be made publicly available (http://nhird.nhri.org.tw/en/index.html).


Articles from Naunyn-Schmiedeberg's Archives of Pharmacology are provided here courtesy of Springer

RESOURCES